Can the application of graphene oxide contribute to the fight against COVID-19? Antiviral activity, diagnosis and prevention.
Antiviral activity
Biosensors
COVID-19
Coronavirus SARS-CoV-2
Detection
Graphene oxide
Pandemic
Prevention
Journal
Current research in pharmacology and drug discovery
ISSN: 2590-2571
Titre abrégé: Curr Res Pharmacol Drug Discov
Pays: Netherlands
ID NLM: 9918300982506676
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
06
2021
revised:
20
09
2021
accepted:
02
10
2021
entrez:
6
12
2021
pubmed:
7
12
2021
medline:
7
12
2021
Statut:
ppublish
Résumé
COVID-19 is an infectious disease that affects the respiratory system and is caused by the novel coronavirus SARS-CoV-2. It was first reported in Wuhan, China, on December 31, 2019, and has affected the entire world. This pandemic has caused serious health, economic and social problems. In this situation, the only solution to combat COVID-19 is to accelerate the development of antiviral drugs and vaccines to mitigate the virus and develop better antiviral methods and excellent diagnostic and prevention techniques. With the development of nanotechnology, nanoparticles are being introduced to control COVID-19. Graphene oxide (GO), an oxidized derivative of graphene, is currently used in the medical field to treat certain diseases such as cancer. It is characterized by very important antiviral properties that allow its use in treating certain infectious diseases. The GO antiviral mechanism is discussed by the virus inactivation and/or the host cell receptor or by the physicochemical destruction of viral species. Moreover, the very high surface/volume ratio of GO allows the fixation of biomolecules by simple absorption. This paper summarizes the different studies performed on GO's antiviral activities and discusses GO-based biosensors for virus detection and approaches for prevention.
Identifiants
pubmed: 34870157
doi: 10.1016/j.crphar.2021.100062
pii: S2590-2571(21)00049-3
pmc: PMC8491929
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100062Informations de copyright
© 2021 Published by Elsevier B.V.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Nanoscale. 2020 Oct 1;12(37):19043-19067
pubmed: 32960195
ACS Appl Mater Interfaces. 2015 Sep 30;7(38):21571-9
pubmed: 26370151
Nanoscale. 2017 Oct 26;9(41):16086-16092
pubmed: 29034936
Nanoscale. 2017 Mar 17;9(11):3774-3783
pubmed: 28266670
Eye (Lond). 2020 Jul;34(7):1155-1157
pubmed: 32029919
Int J Environ Res Public Health. 2016 Apr 19;13(4):430
pubmed: 27104546
Biosens Bioelectron. 2018 Feb 15;100:85-88
pubmed: 28865242
Microchem J. 2021 Jan;160:105606
pubmed: 33052148
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Vaccine. 2007 Jan 8;25(4):729-40
pubmed: 17049691
Curr Top Microbiol Immunol. 2018;419:1-42
pubmed: 28643204
J Virol. 2012 Apr;86(7):3995-4008
pubmed: 22278237
J Virol. 2018 Jul 17;92(15):
pubmed: 29769348
J Clin Med. 2020 May 18;9(5):
pubmed: 32443459
Nat Biotechnol. 2020 Jul;38(7):870-874
pubmed: 32300245
Adv Mater. 2021 Feb;33(7):e2006647
pubmed: 33349975
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Annu Rev Virol. 2016 Sep 29;3(1):237-261
pubmed: 27578435
Small. 2015 Mar;11(9-10):1171-6
pubmed: 25285820
ACS Biomater Sci Eng. 2017 Apr 10;3(4):619-627
pubmed: 33429629
Biochem Biophys Res Commun. 2020 Nov 26;533(1):195-200
pubmed: 32958250
J Nanobiotechnology. 2005 Jun 29;3:6
pubmed: 15987516
ACS Nano. 2020 Apr 28;14(4):5135-5142
pubmed: 32293168
ACS Nano. 2021 Jun 15;:
pubmed: 34128653
J Microbiol Immunol Infect. 2021 Apr;54(2):159-163
pubmed: 32265180
Colloids Surf B Biointerfaces. 2021 Mar;199:111509
pubmed: 33340933
Biomed Res Int. 2021 Jun 10;2021:5518999
pubmed: 34222470
Med Hypotheses. 2020 Nov;144:110031
pubmed: 33254479
J Virol. 2004 Nov;78(22):12672-6
pubmed: 15507655
iScience. 2021 Jul 23;24(7):102788
pubmed: 34222841
Langmuir. 2008 Oct 7;24(19):10560-4
pubmed: 18759411
Clin Infect Dis. 2020 Jul 28;71(15):870-874
pubmed: 32215613
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
Arch Virol. 2012 Jul;157(7):1411-22
pubmed: 22481600
Int J Biol Macromol. 2019 Apr 1;126:151-158
pubmed: 30584937
Nanomicro Lett. 2018 Jul;10(3):53
pubmed: 30079344
Med Drug Discov. 2021 May 25;:100099
pubmed: 34056572
Nat Rev Microbiol. 2019 Mar;17(3):181-192
pubmed: 30531947
Adv Healthc Mater. 2016 Nov;5(22):2922-2930
pubmed: 27581958
Nano Today. 2020 Aug;33:100883
pubmed: 32382315
Viral Immunol. 2004;17(2):220-33
pubmed: 15279701
Virology. 2005 Apr 10;334(2):160-5
pubmed: 15780866
Bioelectrochemistry. 2018 Aug;122:199-205
pubmed: 29660648
Nanomedicine. 2017 Feb;13(2):549-557
pubmed: 27558351
Int J Hyg Environ Health. 2001 Jul;203(5-6):401-9
pubmed: 11556144
Nanomaterials (Basel). 2019 Aug 18;9(8):
pubmed: 31426617
ACS Appl Mater Interfaces. 2014 Jan 22;6(2):1228-35
pubmed: 24364493
Mater Sci Eng C Mater Biol Appl. 2020 Mar;108:110465
pubmed: 31924022
Mater Sci Eng C Mater Biol Appl. 2019 Dec;105:110052
pubmed: 31546360
Med Hypotheses. 2020 Nov;144:110253
pubmed: 33254558
Sci Rep. 2017 Apr 10;7:46169
pubmed: 28393929